Company Overview and News

27
Short seller who foresaw Valeant crash now bets on Tesla falling

2018-10-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
VRX LHHMQ MDXG BHS

27
MDXG / MiMedx Group, Inc. / PETIT PARKER H - SC 13D/A (Activist Investment)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MDXG

28
MDXG / MiMedx Group, Inc. / PETIT PARKER H - SC 13D/A (Activist Investment)

2018-10-10 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MDXG

40
MDXG / MiMedx Group, Inc. 8-K (Current Report)

2018-10-04 sec.gov - 13
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
MDXG

50
Most Heavily Shorted Stocks Tank In September

2018-09-28 seekingalpha - 11
We published our regularly updated Short Interest Report earlier today in order to show clients which areas of the market are seeing the biggest increases and decreases in short interest levels. A supplement to the report is the table below highlighting the most heavily shorted stocks in the S&P 1500.
DDS MDXG MDCO AAOI ICHR

28
MiMedx Stock Shoots Higher After Earlier Drop

2018-09-23 investorplace - 1
MiMedx (NASDAQ:MDXG) had a mixed day on Friday that ultimately resulted in a surge as the company is seeking to ameliorate some of its past transgressions.
MDXG

36
MDXG / MiMedx Group, Inc. 8-K (Current Report)

2018-09-21 sec.gov - 9
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 <
MDXG

40
MDXG / MiMedx Group, Inc. 8-K (Current Report)

2018-09-20 sec.gov - 13
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
MDXG

307
Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha - 9
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
HIBB JWN DKS AVGO APRN PCB SODA AMC TMUS PDYPF AKCA JONE COUP SOLO REV MESA CZR LJPC VZ HEAR FCAU BRC MGM GCO FB ULTA IGT TM IRBT VCNX CTXR LB GMVHF MTCH DBX KS JNEEP AAPL USAK TSG ZAGG PRTY KSU DDS MRVL COOL HMC GBX TSCO DSKE MU DG WRK BYD LOW LRCX TXN CTRP TWX HA SKYW GNC RCL RH UAL PFCF AMZN TWTR CATO BKS VLKAY OSTK AAL BKE BBY GWRE MDLZ GME ON NSC NAV GOOGL QCOM HD XLNX CHDN CPB WDAY FND JBLU QSII WIMHY ALK ADBE MDXG GM GOGO CROX DAL CWH WIMHF F TECH PANW COST M SAVE WMH W S PEP URBN

35
MDXG / MiMedx Group, Inc. FORM 8-K (Current Report)

2018-08-31 sec.gov - 8
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 MDXG

44
Your Daily Pharma Scoop: Xarelto's Mixed Bag, Zai Lab Abandons, Lynparza Okayed

2018-08-28 seekingalpha
Discussion: The European Commission has approved a regimen of Xarelto (rivaroxaban) (2.5 mg twice daily) plus acetylsalicylic acid (75-100 mg once daily) for the prevention of blood clots in adult patients with coronary artery disease (CAD). The approval also includes patients suffering from symptomatic peripheral artery disease (PAD) who are at high risk for ischemic events. The drug is being jointly developed by Bayer (OTCPK:BAYRY) and Johnson & Johnson (NYSE:JNJ) unit Janssen Research & Development, LLC.
AZN BMXXY MDXG JNJ AZN MRK ZLAB DGE DGE DEO BHS

27
Amniofix Injectable Reimbursement: The Sky Is Falling

2018-08-17 seekingalpha
On 8/14/2018, Gretchen Morgenson and Charley Grant reported on WSJ that HCSC, a Blue-Cross-Blue-Shield member, would stop reimbursing Amniofix Injectable as of August 1, due to an "unreported" policy change.
MDXG NYTAB

47
PRESS DIGEST- Wall Street Journal - Aug 16

2018-08-16 reuters
Aug 16 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
SYMC MDXG TMUSP TMUS P LYV

28
Insurer Stops Reimbursing for Some MiMedx Products - WSJ

2018-08-14 wsj - 1
A major health insurer said it will stop reimbursing patients for use of injectable amniotic-tissue products made by MiMedx Group Inc. and other manufacturers, saying they are considered “experimental, investigational and/or unproven for all indications.”
MDXG

27
MDXG / MiMedx Group, Inc. NT 10-Q

2018-08-13 sec.gov
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 MDXG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 602496101